Novavax Share Price Decline: Undervalued or Overvalued?

Novavax (NVAX) shares have declined 13.53% in the past 30 days and 94.06% over the past five years. Despite occasional rallies, the stock price is far below analyst targets. Investors must decide whether the current price reflects a deeply discounted turnaround bet or the market's correct pricing of limited future growth. The global vaccine market is expected to increase, driven by factors such as aging populations and emerging infectious diseases, expanding Novavax's addressable market and supporting long-term revenue growth.